Urine-Based Liquid Biopsy for Nonurological Cancers
- PMID: 30986103
- PMCID: PMC6482900
- DOI: 10.1089/gtmb.2018.0189
Urine-Based Liquid Biopsy for Nonurological Cancers
Abstract
Aims: The use of circulating cell-free DNA for detection of cancer genetics has been studied extensively. Liquid biopsy often refers to the use of blood as a minimally invasive source of body fluid for detecting circulating tumor DNA (ctDNA). However, urine collection, which is completely noninvasive, has been shown to also have great promise to serve as an alternate body fluid source for ctDNA. In this review article, we focus on the clinical utility of urine for genetic liquid biopsy of nonurological cancers.
Conclusion: Although still in early stages as compared with blood-based liquid biopsy, recent studies have demonstrated the value of urine-based liquid biopsies for: nonurological cancer screening; early detection; monitoring for recurrence and metastasis; and therapeutic efficacy. Overall, the completely noninvasive and patient-friendly nature of the urine-based biopsy warrants further development and offers a promising alternative to blood-based biopsies.
Keywords: cancer; liquid biopsy; nonurological; urine.
Conflict of interest statement
S.J. and S.Y.L. are employees of JBS Science, Inc. W.S. is the president and stockholder of JBS Science, Inc.
Figures

Similar articles
-
Liquid Biopsy in Solid Malignancy.Genet Test Mol Biomarkers. 2019 Apr;23(4):284-296. doi: 10.1089/gtmb.2018.0237. Epub 2019 Mar 27. Genet Test Mol Biomarkers. 2019. PMID: 30916594 Free PMC article. Review.
-
Circulating cell-free tumor DNA analysis in pediatric cancers.Mol Aspects Med. 2020 Apr;72:100819. doi: 10.1016/j.mam.2019.09.003. Epub 2019 Sep 25. Mol Aspects Med. 2020. PMID: 31563277 Review.
-
Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology.Crit Rev Oncol Hematol. 2019 Sep;141:36-42. doi: 10.1016/j.critrevonc.2019.06.005. Epub 2019 Jun 7. Crit Rev Oncol Hematol. 2019. PMID: 31212145 Review.
-
Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer.Cancer Biomark. 2020;27(1):29-37. doi: 10.3233/CBM-182344. Cancer Biomark. 2020. PMID: 31658042
-
Urinary Biomarkers in Tumors: An Overview.Methods Mol Biol. 2021;2292:3-15. doi: 10.1007/978-1-0716-1354-2_1. Methods Mol Biol. 2021. PMID: 33651347 Review.
Cited by
-
Urine biopsy technologies: Cancer and beyond.Theranostics. 2020 Jun 22;10(17):7872-7888. doi: 10.7150/thno.44634. eCollection 2020. Theranostics. 2020. PMID: 32685026 Free PMC article. Review.
-
cfRNAs as biomarkers in oncology - still experimental or applied tool for personalized medicine already?Rep Pract Oncol Radiother. 2020 Sep-Oct;25(5):783-792. doi: 10.1016/j.rpor.2020.07.007. Epub 2020 Aug 11. Rep Pract Oncol Radiother. 2020. PMID: 32904167 Free PMC article. Review.
-
Liquid biopsy: Comprehensive overview of circulating tumor DNA (Review).Oncol Lett. 2024 Sep 13;28(5):548. doi: 10.3892/ol.2024.14681. eCollection 2024 Nov. Oncol Lett. 2024. PMID: 39319213 Free PMC article. Review.
-
The impact of preanalytical variables on the analysis of cell-free DNA from blood and urine samples.Front Cell Dev Biol. 2024 May 9;12:1385041. doi: 10.3389/fcell.2024.1385041. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38784382 Free PMC article. Review.
-
Urinary Cell-Free DNA in Liquid Biopsy and Cancer Management.Clin Chem. 2022 Dec 6;68(12):1493-1501. doi: 10.1093/clinchem/hvac122. Clin Chem. 2022. PMID: 36213956 Free PMC article. Review.
References
-
- Anker P. (2000) Quantitative aspects of plasma/serum DNA in cancer patients. Ann N Y Acad Sci 906:5–7 - PubMed
-
- Anker P, Lyautey J, Lederrey C, Stroun M. (2001) Circulating nucleic acids in plasma or serum. Clinica Chimica Acta 313:143–146 - PubMed
-
- Anker P, Mulcahy H, Chen XQ, Stroun M. (1999) Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 18:65–73 - PubMed
-
- Anker P, Stroun M. (2002) Progress in the knowledge of circulating nucleic acids: plasma RNA is particle-associated. Can it become a general detection marker for a cancer blood test? Clin Chem 48:1210. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical